Skip to main content
Premium Trial:

Request an Annual Quote

MoBiTec to Distribute Amoy's MDx Products in Germany

NEW YORK (GenomeWeb) – MoBiTec today announced a deal for the distribution of Amoy Diagnostics products in Germany.

Based in Xiamen, China, Amoy provides molecular diagnostics products and services, including tests for detecting mutations and measuring gene expression in formalin-fixed, paraffin-embedded cancer tissue. Its assays are based on a proprietary real-time PCR technology dubbed ADx-ARMS. Its tests for EGFR, KRAS, BRAF, PIK3CA, and EML4-ALK are CE-marked for marketing in Europe and Chinese Food and Drug Administration-approved for clinical use in China. Its ROS1 and ERCC1 assays are CE-marked for IVD use in Europe.

MoBiTec said Amoy's assays are designed and tested in an ISO 13485-certified laboratory and assembled in a dedicated GMP-compliant manufacturing plant, and have been validated to run on several PCR platforms commonly used by diagnostic labs.

Amoy also has kits for detecting mutations in JAK2, KIT, BCR-ABL, PIK3CA, EML4-ALK, P53, and the RET oncogene.

Based in Göttingen, Germany, MoBiTec offers its own research tools for molecular and cell biology research and distributes products from other companies.

Financial and other terms of the agreement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.